openPR Logo
Press release

Creative Peptides Released GMP Synthesis Service

09-04-2018 10:06 AM CET | Health & Medicine

Press release from: Creative Peptides

Located in Shirley, New York, the world’s leading peptide supplier Creative Peptides announced the launch of its GMP synthesis (https://www.creative-peptides.com/services/custom-gmp-peptide-synthesis-services.html ) business on August 29, 2018. Now this company is focused on the development and GMP manufacturing of pharmaceutical grade peptides.
As the demand of pharmaceutical market continues to grow, more and more pharmas and research institutions choose the CMO and CRO models to expand their businesses, which is more cost-saving, efficient without additional expenses on staff, equipment and other infrastructure. Creative Peptides has become the first choice to outsource the manufacturing of peptides or active pharmaceutical ingredients (APIs) in any quantities, owing to its world-in-class technologies, strong technical staff and strict quality control systems.
“We are able to produce GMP peptides, APIs in annual quantities as needed by our customers. The availability of low-cost active pharmaceutical ingredients from our company has had a big impact in the international community,” said Dr. Robert Martinez, Head of Creative Peptides’ synthesis businesses, in a statement. “Our robust, economical manufacturing processes will definitely help optimize the costs of drug discovery and development. A full range of synthetic technologies are available. But as to which technology to be used, the final choice depends on the sequence length, the scale, and the specific project requirements.”
The GMP synthesis range at Creative Peptides includes:
Large-Scale Liquid (Solution) Phase Peptide Synthesis (LPPS)
Large-Scale Solid Phase Peptide Synthesis (SPPS)
Large-Scale Hybrid Fragment Synthesis Peptide
Modifications
Large-Scale Purification
Large-Scale Isolation
Whenever and wherever, quality control is the top priority for Creative Peptides. The GMP production sites were designed in strict accordance to US-FDA guidelines. All have passed US-FDA inspections. Currently this company is qualified for the manufacturing of generic APIs in compliance with ICH guidelines including Q7 and other related and applicable sections.
>98% purity of the GMP synthetic products is guaranteed. Standard QC tests before releasing GMP products are also provided. Extra tests can be made as well according to the requests of clients.

About Creative Peptides
With a high profile team of experts in multiple fields such as peptide technology and synthetic chemistry, Creative Peptides not only provides various research peptides, like anti-pigmentation peptide (https://www.creative-peptides.com/product/anti-pigmentation-54.html), neoantigen (https://www.creative-peptides.com/services/neoantigen-peptides-vaccine-synthesis-service.html), glucagon like peptides, but also dedicates to solving the problems that trouble its clients by offering various GMP synthesis services.

Creative Peptides

45-16 Ramsey Road, Shirley, NY 11967, USA

Caroline Miller

contact@creative-peptides.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Peptides Released GMP Synthesis Service here

News-ID: 1217565 • Views:

More Releases from Creative Peptides

Creative Peptides Released One-Stop Solution for All Peptide Drug Conjugate Need …
New York, United States-Sep 5, 2022-Peptide drug conjugate (PDC) is emerging as a novel type of conjugate drug, showing advantageous features over antibody-drug conjugates (ADCs). As a dedicated peptide manufacturer, Creative Peptides provides a one-stop solution for all peptide drug bioconjugation needs to help pharmaceutical clients bring more PDCs to the market. Structurally, PDC mainly contains three elements-cytotoxin, linker, and targeted peptide, in which a specific peptide sequence covalently connects with
Creative Peptides Rolls Out PNA FISH Probes with High Sensitivity and Specific H …
New York, United States - March 22, 2022-Creative Peptides, as a pioneering biomedical technology company in the United States, is qualified to provide highly specific products and services for life science research. To promote PNA biology research, Creative Peptides offers various PNA FISH probes such as telomere probes and CAG repeat probes. Fluorescence in situ hybridization (FISH) is a cytogenetic method to detect and target the presence or absence of specific

More Releases for Peptide

Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established
What's driving the Customized Peptide Synthesis Market Growth? | Key Players are …
The customized peptide synthesis market is projected to generate a revenue of $390.0 million by 2024 as per a recent P&S Intelligence study. The market is being progressively driven by technological innovations, growing burden of cancer and infectious diseases, increasing investments and funding for protein-based research, and rising research activities in synthetic biology. Download free report sample at: https://www.psmarketresearch.com/market-analysis/customized-peptide-synthesis-market/report-sample There are two main types of products available in the customized peptide synthesis
Customized Peptide Synthesis Market 2019-2024 by Top Key Players are GenScript, …
Customized peptide synthesis market is forecasted to generate revenue of $390.0 million by 2024. The market is mainly driven by increasing investments and funding for protein-based research, technological innovations, growing burden of cancer and infectious diseases, and increasing research activities in the field of synthetic biology. Download free report sample at: https://www.psmarketresearch.com/market-analysis/customized-peptide-synthesis-market/report-sample The different types of products available in the customized peptide synthesis market are reagents and equipment. Reagents category is expected
Peptide Synthesis Market Increasing Demand & Latest Trend with Genscript, AnaSpe …
HTF MI recently introduced United States Peptide Synthesis Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Bachem, PolyPeptide, GL Biochem, Xinbang, Hybio, USVPeptides, Thermofischer, ScinoPharm, Genscript,
Global Peptide Therapeutics Market: Cancer Treatment to Surface as Key Applicati …
Market Research Reports Search Engine (MRRSE) has been acting as an impressive data source when it comes to evaluating various industrial verticals. The research report titled “Global Peptide Therapeutics Market” offers a clear insight about the Peptide Therapeutics assessed over the global platform. This analysis proves beneficial for readers & new investors who are aiming to enter the market for Peptide Therapeutics in the near future. Click to Request a Sample:
Peptide Based Cancer Therapeutics Marke For peptide based cancer therapeutics ov …
About Peptide Based Cancer Therapeutics Market Popularity of peptide based cancer therapeutics is on the rise, owing to the positive outlook on their efficiency in treating cancer. According to the latest report published by Fact.MR, the global market for peptide based cancer therapeutics is set to reflect an above average CAGR during 2017 to 2022, to reach a valuation in excess of US$ 11,100 Mn. Incessant development in drug